Oncology pathway explorer
AMPK
Scientific explanation
AMP-activated protein senses AMP:ATP ratio, restraining anabolic signalling and favouring catabolic programmes including fatty-acid oxidation.
Cancers where relevant
Compounds that intersect this pathway
Modest complex I inhibition raises AMP:ATP, activating and restraining hepatic and -linked anabolism. Direct antineoplastic efficacy is not established from that pharmacology alone.
Evidence in mapped cancers: Clinical / Human Evidence · In Vivo · In Vitro · Mechanistically Plausible
AMP mimetic that activates in experimental systems. Research tool, not an approved oncology medicine.
Evidence in mapped cancers: In Vitro · In Vivo · Hypothesis-Generating
Berberine
Isoquinoline alkaloid that can inhibit complex I and activate in metabolic models, with additional -independent reports. Not an approved antineoplastic.
Evidence in mapped cancers: In Vitro · In Vivo · Mechanistically Plausible
Resveratrol
Stilbene with sirtuin/-related and anti-inflammatory reports in models. Pharmacokinetic limits and mixed trials caution against efficacy claims.
Convergence partners
Other pathways that co-occur with AMPK on mapped adjunct records: mTOR, Glycolysis, Mitochondrial oxidative phosphorylation.
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.